Sign In
Free Newsletter
Embecta to acquire UK medical device maker Owen Mumford for $200M
The addition will expand the Parsippany-based company's focus beyond diabetes into drug discovery, as well as accelerate its global growth strategy.
Novo Nordisk halves Ozempic price to $499 for US patients
As part of an effort to improve access to authentic versions of its GLP-1 medications, the drugmaker is cutting the cost of its popular diabetes drug.
ADA, Leapfrog Group recognize 3 NJ hospitals for diabetes care
In total, 36 health care providers across 12 states were honored "for demonstrating their commitment to patient safety and improving the lives of people living with diabetes."
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
An industry group filed the lawsuit after the health regulator removed semaglutide from its shortage list and told manufacturers they need to stop producing unbranded versions within the next 60 to 90 days.
For the win: NJ companies kick off 2024 with new sports partnerships
From helping cold-weather athletes beat dry skin to "egg"ceptional pickleball perks, see which New Jersey brands are getting into the spirit of the game this year.
Novo Nordisk, Eli Lilly sued over ‘stomach paralysis’ claims
Ozempic is making headlines again, this time for facing a lawsuit from a Louisiana woman who alleges the pharmaceutical companies behind that drug and Mounjaro failed to warn patients about health risks associated with their popular Type 2 diabetes medications.
Sanofi to slash price of insulin by 78%
In addition to the adjustment for its most popular product, the company said it will also cap out-of-pocket costs for the diabetes medicine at $35 per month for people with private insurance.
Sanofi to acquire Provention Bio in $2.9B deal
Following the buyer's $35 million equity investment from February 2023, the transaction will help to expand the global health care company's expertise in diabetes treatment.
Embecta opens new global headquarters in Parsippany
One of the largest pure-play diabetes care companies in the world, the move follows its April 2022 spinoff from Franklin Lakes-based Becton, Dickinson and Co.
Side effects may include weight loss – and supply shortages
Novo Nordisk is working to resolve shortages of Ozempic and Wegovy by the end of the year.
BD completes spinoff of diabetes biz, launching embecta
No foolin': embecta is officially a separate company as of April 1.
BD’s diabetes spinoff embecta gets board OK (updated)
The separation is consistent with the Franklin Lakes-based company's growth strategy, allowing it to focus on core innovation priorities.
